Recursion Pharmaceuticals, Inc. (RXRX) — 8-K Filings

8-K Filings (28)

• 8-K Filing — Dec 8, 2025
• Recursion Pharmaceuticals Files 8-K — Nov 26, 2025 Risk: low
  Recursion Pharmaceuticals, Inc. filed an 8-K on November 26, 2025, reporting on other events and financial statements. The filing details the company's principa
• Recursion Pharmaceuticals Files 8-K — Oct 29, 2025 Risk: low
  Recursion Pharmaceuticals, Inc. filed an 8-K on October 29, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about th
• Recursion Pharmaceuticals Files 8-K on Equity Sales — Jul 8, 2025 Risk: medium
  Recursion Pharmaceuticals, Inc. filed an 8-K on July 8, 2025, reporting on unregistered sales of equity securities, Regulation FD disclosures, and other events.
• Recursion Pharmaceuticals Files 8-K on Shareholder Votes — Jun 18, 2025 Risk: low
  Recursion Pharmaceuticals, Inc. filed an 8-K on June 18, 2025, to report on the submission of matters to a vote of its security holders. The filing does not con
• 8-K Filing — Jun 10, 2025
• Recursion Pharmaceuticals Files 8-K — May 9, 2025 Risk: low
  Recursion Pharmaceuticals, Inc. filed an 8-K on May 9, 2025, reporting other events and financial statements. The filing does not contain specific financial fig
• Recursion Pharma Names New CMO, Chief Medical Officer Departs — Mar 18, 2025 Risk: medium
  Recursion Pharmaceuticals, Inc. announced on March 15, 2025, the departure of Chief Medical Officer, Dr. Blake W. Johnson. The company also announced the appoin
• Recursion Pharmaceuticals Files 8-K — Jan 13, 2025 Risk: low
  Recursion Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing does n
• Recursion Pharmaceuticals Files 8-K — Dec 17, 2024 Risk: low
  Recursion Pharmaceuticals, Inc. filed an 8-K on December 17, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain
• Recursion Pharma Appoints New CMO, CBO; Gibson Departs — Dec 3, 2024 Risk: medium
  Recursion Pharmaceuticals, Inc. announced on December 2, 2024, the appointment of Dr. Amy Abernethy as Chief Medical Officer and Dr. Laura LaVoie as Chief Busin
• Recursion Pharma Completes Cyclica Acquisition, Sees Exec Changes — Nov 20, 2024 Risk: medium
  Recursion Pharmaceuticals, Inc. announced on November 19, 2024, the completion of its acquisition of Cyclica Inc. for an undisclosed amount. The company also re
• Recursion Pharmaceuticals Files 8-K — Nov 13, 2024 Risk: low
  Recursion Pharmaceuticals, Inc. filed an 8-K on November 13, 2024, to report other events and financial statements. The filing does not contain specific details
• Recursion Pharmaceuticals Enters Material Definitive Agreement — Nov 6, 2024 Risk: medium
  Recursion Pharmaceuticals, Inc. announced on November 5, 2024, that it entered into a Material Definitive Agreement. The filing also includes other events and f
• Recursion Pharma Acquires Subsidiary for $10M — Oct 2, 2024 Risk: low
  Recursion Pharmaceuticals, Inc. announced on October 2, 2024, that it has entered into a definitive agreement to acquire Recursion Pharmaceuticals GmbH, a wholl
• Recursion Pharmaceuticals Files 8-K — Sep 3, 2024 Risk: low
  Recursion Pharmaceuticals, Inc. filed an 8-K on September 3, 2024, reporting on various events. The filing includes information related to Regulation FD disclos
• Recursion Pharmaceuticals Files 8-K — Aug 28, 2024 Risk: low
  Recursion Pharmaceuticals, Inc. filed an 8-K on August 28, 2024, to report other events and financial statements. The filing does not contain specific details a
• Recursion Pharma Appoints New Chief Medical Officer — Aug 8, 2024 Risk: medium
  Recursion Pharmaceuticals, Inc. announced on August 6, 2024, the appointment of Amy Abernethy, M.D., Ph.D., as Chief Medical Officer. Dr. Abernethy previously s
• Recursion Pharmaceuticals Files 8-K — Aug 6, 2024 Risk: low
  On August 6, 2024, Recursion Pharmaceuticals, Inc. filed an 8-K report. The filing does not contain specific details about new events, material agreements, or f
• Recursion Pharma Partners with NVIDIA for AI Drug Discovery — Jun 27, 2024 Risk: medium
  Recursion Pharmaceuticals, Inc. announced on June 26, 2024, that it has entered into a collaboration and license agreement with NVIDIA Corporation. This agreeme
• Recursion Pharma Partners with NVIDIA for AI Drug Discovery — Jun 24, 2024 Risk: medium
  Recursion Pharmaceuticals, Inc. announced on June 24, 2024, that it entered into a strategic collaboration with NVIDIA Corporation. This collaboration aims to a
• Recursion Pharmaceuticals Reports on Shareholder Vote Outcomes — Jun 7, 2024 Risk: low
  Recursion Pharmaceuticals, Inc. filed an 8-K on June 7, 2024, to report on matters submitted to a vote of its security holders on June 3, 2024. The filing detai
• Recursion Pharma CFO Departs, Auditor Resigns — May 24, 2024 Risk: medium
  Recursion Pharmaceuticals, Inc. announced on May 21, 2024, the departure of its Chief Financial Officer, Amy Reilly. The company also disclosed that its indepen
• Recursion Pharmaceuticals Appoints New Chief Legal Officer — Apr 16, 2024 Risk: low
  Recursion Pharmaceuticals, Inc. announced on April 15, 2024, the appointment of Amy Reilly as Chief Legal Officer and General Counsel, effective April 15, 2024.
• Recursion Pharma Files 8-K on Financial Results and Disclosures — Feb 27, 2024 Risk: medium
  Recursion Pharmaceuticals, Inc. filed an 8-K on February 27, 2024, reporting on its results of operations and financial condition. The filing also included Regu
• Recursion Pharma Files Routine 8-K; No Major Changes Reported — Feb 7, 2024
  Recursion Pharmaceuticals, Inc. filed an 8-K on February 7, 2024, reporting an event that occurred on February 6, 2024. This filing is a standard current report
• Recursion Pharma Amends Bylaws/Articles; Nasdaq Listing Confirmed — Jan 31, 2024
  Recursion Pharmaceuticals, Inc. filed an 8-K on January 31, 2024, reporting an event on January 25, 2024, related to amendments to its Articles of Incorporation
• Recursion Pharma Files 8-K for Reg FD Disclosure — Jan 8, 2024
  Recursion Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose information under Regulation FD and to file financial statements and exhibits. This

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX